Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
36.94
-0.11 (-0.30%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Apogee Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Apogee Therapeutics stock have an average target of 91.33, with a low estimate of 89 and a high estimate of 95. The average target predicts an increase of 147.24% from the current stock price of 36.94.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 13, 2025.
Analyst Ratings
The average analyst rating for Apogee Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $95 | Strong Buy | Initiates | $95 | +157.17% | Mar 13, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Feb 10, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 12, 2024 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $95 → $110 | Strong Buy | Reiterates | $95 → $110 | +197.78% | Dec 3, 2024 |
| Wedbush | Wedbush | Buy Maintains $87 → $90 | Buy | Maintains | $87 → $90 | +143.64% | Dec 2, 2024 |
Financial Forecast
Revenue This Year
27.95M
Revenue Next Year
235.64M
from 27.95M
Increased by 743.14%
EPS This Year
-5.12
from -3.30
EPS Next Year
-6.14
from -5.12
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.69 | -4.55 | -4.85 | ||
| Avg | -5.12 | -6.14 | -6.60 | ||
| Low | -6.80 | -10.44 | -10.97 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.